KRAS and neoplasm: Notably, the proportion of PD-L1 TPS (i.e., tumor proportion score) ≥50% was reported in a range of 34 (32) to 41% (48) for KRAS G12C patients compared with 20.4% (32) to 25.9% (48) among KRAS wild-type patients.